Roche says U.S. FDA issues Emergency Use Authorization for Zika test
Roche tablets are seen positioned in front of a displayed Roche logo in this photo illustration shot January 22, 2016. REUTERS/Dado Ruvic/Illustration/File Photo
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
ZURICH (Reuters) - Swiss drugmaker Roche (NYSE: ROG) said on Monday the U.S. Food and Drug Administration (FDA) had issued an Emergency Use Authorization (EUA) for its test for the Zika virus.
"The LightMix Zika test is an easy-to-use molecular diagnostic test that enables healthcare professionals to quickly detect the virus," said Uwe Oberlaender, the head of molecular diagnostics at Basel-based Roche.
The virus has been associated with microcephaly, a birth defect characterized by an unusually small head and potential developmental problems.
(Reporting by Joshua Franklin; Editing by Subhranshu Sahu)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA Grants Priority Review for Genentech’s Actemra® (Tocilizumab) Supplemental Biologics License Application for Giant Cell Arteritis, a Form of Vasculitis
- Trump signs executive orders on manufacturing, infrastructure
- California Governor Brown vows to fight Trump, calls for civility
Create E-mail Alert Related CategoriesReuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!